POAI News and Press, Predictive Oncology Inc. From 12/31/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ll begin this penny stock list in the same manner that I begin all lists of penny stocks: With a caveat. Penny stocks are among the most volatile classes of investments. Pretty much everyone interested in this...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced a new time for its annual meeting of stockholders. The meeting was originally scheduled for Dec. 23, 2021, ...

MINNEAPOLIS, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of S...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today issued a year-end corporate update. Among the highlights, the update discussed POAI’s November 2021 acquisi...

EAGAN, Minn., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction. In November 2021, POAI acquired zPREDICTA, ...

Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA will be joining the company’s leadership team as SVP of Strategic Sa...

EAGAN, Minn., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA would be joining the company’s lead...

Predictive Oncology (NASDAQ:POAI) has acquired of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell culture models for drug discovery and development. The acquisition adds a new anticipated revenue stream to Predictive Oncology. Based on zPREDICTA's historical operating res...

EAGAN, Minn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced the acquisition of zPREDICTA , a company pioneering tumor-specific in v...

Predictive Oncology (NASDAQ:POAI): Q3 GAAP EPS of -$0.08 misses by $0.03. Revenue of $0.31M (-35.4% Y/Y) misses by $0.29M. Press Release For further details see: Predictive Oncology EPS misses by $0.03, misses on revenue